SCM
ALGS icon

Silverarc Capital Management’s Aligos Therapeutics ALGS Stock Holding History

Silverarc Capital Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-26,219
Closed -$227K – 63
2024
Q3 		$227K Sell
26,219
-2
-0% -$25 0.05% 69
2024
Q2 		$229K Hold
26,221
– – 0.05% 68
2024
Q1 		$642K Sell
26,221
-519
-2% -$10.3K 0.18% 67
2023
Q4 		$444K Buy
26,740
+1,465
+6% +$25.2K 0.13% 64
2023
Q3 		$472K Hold
25,275
– – 0.14% 69
2023
Q2 		$614K Hold
25,275
– – 0.19% 67
2023
Q1 		$552K Buy
+25,275
New +$966K 0.23% 65
2022
Q3 		– Sell
-2,336
Closed -$71K – 80
2022
Q2 		$71K Buy
2,336
+1,910
+448% +$64.9K 0.02% 68
2022
Q1 		$23 Buy
+426
New +$34.1K 0.01% 68

Other funds holding ALGS

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
TI
Trexquant Investment Stamford, Connecticut $13.9B AUM 31.98% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Silverarc Capital Management's ALGS Position: Q4 2024 in Review

Silverarc Capital Management sold out of Aligos Therapeutics (ALGS) in Q4 2024, closing a stake of 26,219 shares — an estimated $227K sold.

Silverarc Capital Management first reported a position in ALGS in Q1 2022 and held it in 9 quarters. The position peaked at $642K in Q1 2024. 34 funds tracked by Wall St. Rank hold ALGS as of Q4 2024.

  • Silverarc Capital Management reported no remaining Aligos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Silverarc Capital Management sold 26,219 Aligos Therapeutics shares in Q4 2024, an estimated $227K.
  • Silverarc Capital Management first reported a position in Aligos Therapeutics in Q1 2022 and held it in 9 quarters.
  • Silverarc Capital Management's Aligos Therapeutics position peaked at $642K in Q1 2024.
  • 34 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q4 2024.

Based on Silverarc Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.